Compare
AbbVie vs Ligand Pharmaceuticals (ABBV vs LGND)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Ligand Pharmaceuticals (LGND) +60.8%; so far this year the figures are +27.5% and +62.0%.
AbbVie is the larger company by market value, about 84.1 times the size of Ligand Pharmaceuticals.
On trailing earnings, ABBV trades at 50.1 times and LGND at 133.1 times.
Revenue grew +10.7% at ABBV and +1.0% at LGND over the last year.
ABBV yields 2.38%. LGND pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | LGND | |
|---|---|---|
| Price | $291.31 | $306.20 |
| 1-day | +1.07% | +2.41% |
| YTD | +27.49% | +61.95% |
| 1 year | +34.39% | +60.84% |
| 3 years | +104.47% | +474.48% |
| Market cap | $514.9B | $6.1B |
| P/E | 50.1 | 133.1 |
| P/S | 7.80 | 24.13 |
| P/B | — | 6.37 |
| Revenue growth | +10.70% | +1.00% |
| EPS growth | +340.20% | +13.30% |
| Gross margin % | 73.7 | 96.6 |
| Net margin % | 15.7 | 20.3 |
| ROE % | — | 5.4 |
| Debt / equity | — | 1.17 |
| FCF yield % | 3.7 | 1.5 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.85 |
| RSI (14) | 59.7 | 50.1 |
| Technical rating |